phase readout
saveNCT06616584: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
community read0 votes
Sponsor: SWOG Cancer Research Network. Phase: PHASE2. Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
view source ↗Data sources
last refreshed 5h ago
Found something off?
same company · ±60 days · 6
- earningsREGENERON PHARMACEUTICALS, INC. earningsOct 28, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsJul 30, 2026
- phase 2 completioncemiplimab: Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsApr 29, 2026
- pdufadupilumab: Regeneron Pharmaceuticals Inc — dupilumab (PDUFA)Apr 27, 2026
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2026
related news · 8
- biospaceSanofi pays Regeneron $1B upfront to continue search for Dupixent successor
- statSTAT+: Sanofi, Regeneron expand partnership after Dupixent success
- biospaceThe top 12 companies hiring in biopharma now
- biospaceFDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
- biospace6 immunology targets to sustain a mammoth I&I market
- biospace9 companies hiring in Pennsylvania now
- biospaceTrending: Top biopharma disciplines with jobs live now
- biospaceBiopharma hiring hotspots: States, disciplines where demand is highest
comments(0)
5-min edit window · permanent after that